Related Experiment Video
Updated: Jul 3, 2025
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors
Weijian Zhou1, Gaoshaer Yeerkenbieke1, Yumei Zhang1,2
1Department of Oncology, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, 200123, China.
Purpose:
Guanylate binding protein 4 (GBP4) is induced by interferons and various cytokines and has been recognized as functionally relevant in numerous types of human cancers. While the role of GBP4 in cancer has been preliminarily summarized, its correlation with antitumor immunity remains unclear and requires further research.
Methods:
First, a comprehensive pan-cancer analysis was conducted, focusing on GBP4's expression patterns and immunological functions. Subsequently, we explored the correlations between GBP4 and immunological features within the tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) patients. Additionally, we examined the relationships between GBP4 and emerging immunobiomarkers, such as N6-methyladenosine (m6A) genes. Moreover, we assessed the utility of GBP4 in predicting the clinical characteristics and treatment responses of patients with NSCLC.
Results:
Pan-cancer analysis revealed that GBP4 plays a positive role in most cancer types via the majority of immunomodulators. Furthermore, GBP4 demonstrated positive associations with immunomodulatory factors, tumor-infiltrating immune cells (TIICs) and inhibitory immune checkpoints. Remarkably, the expression of GBP4 was found to be a predictor of significantly enhanced responsiveness to anti-EGFR therapy and immunotherapy.
Conclusions:
GBP4 expression profiles offer a promising avenue for identifying highly immunogenic tumors across a wide spectrum of cancers. GBP4 holds potential as a robust pan-cancer biomarker for assessing the immunological characteristics of tumors, with particular relevance to its ability to predict therapeutic responses, notably in the context of anti-EGFR therapy and immunotherapy.
Insights
Guanylate binding protein 4 (GBP4) is a promising pan-cancer biomarker. Its expression predicts enhanced antitumor immunity and better responses to immunotherapy and anti-EGFR therapy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Guanylate binding protein 4 (GBP4) is interferon-induced and implicated in human cancers.
- Its precise role in antitumor immunity and as a predictive biomarker remains largely uncharacterized.
Purpose of the Study:
- To investigate the pan-cancer expression patterns and immunological functions of GBP4.
- To explore GBP4's correlation with the tumor microenvironment (TME) and immunobiomarkers in non-small cell lung cancer (NSCLC).
- To assess GBP4's utility in predicting clinical characteristics and treatment responses in NSCLC.
Main Methods:
- Comprehensive pan-cancer analysis of GBP4 expression and immunological functions.
- Correlation analysis of GBP4 with TME features, immune cells, and m6A genes in NSCLC.
- Evaluation of GBP4 as a predictive biomarker for clinical outcomes and therapy response.
Main Results:
- GBP4 expression positively correlates with immunomodulators and tumor-infiltrating immune cells (TIICs) across most cancer types.
- GBP4 is associated with inhibitory immune checkpoints.
- GBP4 expression predicts enhanced response to anti-EGFR therapy and immunotherapy.
Conclusions:
- GBP4 expression serves as a potential biomarker for identifying highly immunogenic tumors.
- GBP4 is a robust pan-cancer biomarker for assessing tumor immunological characteristics.
- GBP4 predicts therapeutic responses, particularly to anti-EGFR therapy and immunotherapy.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy